Exagen (NASDAQ:XGN) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Exagen (NASDAQ:XGN) released its quarterly earnings results on Tuesday. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02, Zacks reports. Exagen had a negative net margin of 30.36% and a negative return on equity of 84.26%. The firm had revenue of $12.51 million for the quarter, compared to analyst estimates of $13.55 million. During the same period in the previous year, the business earned ($0.31) earnings per share. Exagen updated its FY 2024 guidance to EPS.

Exagen Trading Up 1.4 %

XGN stock traded up $0.04 during midday trading on Wednesday, reaching $2.83. The stock had a trading volume of 12,373 shares, compared to its average volume of 41,811. The company has a debt-to-equity ratio of 1.13, a current ratio of 4.32 and a quick ratio of 4.32. Exagen has a twelve month low of $1.30 and a twelve month high of $3.71. The business has a fifty day simple moving average of $2.84 and a two-hundred day simple moving average of $2.37.

Analysts Set New Price Targets

Separately, William Blair restated an “outperform” rating on shares of Exagen in a research report on Wednesday.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).